Free and total digoxin in serum during treatment of acute digoxin poisoning with fab fragments: Case study

American Journal of Critical Care

Volumn 19, Issue 4, 2010, Pages 387-391

  Eyer, Florian ^a   Steimer, Werner ^b   Müller, Christine ^b   Zilker, Thomas ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; DIGOXIN; IMMUNOGLOBULIN F(AB) FRAGMENT; METILDIGOXIN;

ADULT; ARTICLE; BLOOD; CASE REPORT; FEMALE; HALF LIFE TIME; HUMAN; SUICIDE ATTEMPT;

ADULT; ANTI-ARRHYTHMIA AGENTS; DIGOXIN; FEMALE; HALF-LIFE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MEDIGOXIN; SUICIDE, ATTEMPTED;

EID: 78049501965     PISSN: 10623264     EISSN: None     Source Type: Journal    
DOI: 10.4037/ajcc2009227     Document Type: Article

References (17)

1. Hickey AR, Wenger TL, Carpenter VP, et al. Digoxin Immune Fab therapy in the management of digitalis intoxication: safety and efficacy results of an observational surveillance study. J Am Coll Cardiol. 1991;17:590-598.
2. Lapostolle F, Borron SW, Verdier C, et al. Digoxin-specific Fab fragments as single first-line therapy in digitalis poisoning. Crit Care Med. 2008;36:3014-3018.
3. Lemon M, Andrews DJ, Binks AM, Georgiou GA. Concentrations of free serum digoxin after treatment with antibody fragments. Br Med J (Clin Res Ed). 1987;295:1520-1521.
4. Bateman DN. Digoxin-specific antibody fragments: how much and when? Toxicol Rev. 2004;23:135-143.
5. Schaumann W, Kaufmann B, Neubert P, Smolarz A. Kinetics of the Fab fragments of digoxin antibodies and of bound digoxin in patients with severe digoxin intoxication. Eur J Clin Pharmacol. 1986;30:527-533.
6. Dasgupta A. Therapeutic drug monitoring of digoxin: impact of endogenous and exogenous digoxin-like immunoreactive substances. Toxicol Rev. 2006;25:273-281.
7. Hursting MJ, Raisys VA, Opheim KE, Bell JL, Trobaugh GB, Smith TW. Determination of free digoxin concentrations in serum for monitoring Fab treatment of digoxin overdose. Clin Chem. 1987;33:1652-1655.
8. Johnson BF, Bye C. Maximal intestinal absorption of digoxin, and its relation to steady state plasma concentration. Br Heart J. 1975;37:203-208.
9. Beermann B, Hellstrom K, Rosen A. The absorption of orally administered (12 - 3 H)digoxin in man. Clin Sci. 1972;43: 507-518.
10. Keller F, Blumenthal HP, Maertin K, Rietbrock N. Overall pharmacokinetics during prolonged treatment of healthy volunteers with digoxin and beta-methyldigoxin. Eur J Clin Pharmacol. 1977;12:387-392.
11. Larbig D, Kochsiek K. [Radioimmunochemical assay of digoxin and digoxin derivatives]. Dtsch Med Wochenschr. 1972;97:1310-1312.
12. Argyle JC. Effect of digoxin antibodies on TDx digoxin assay. Clin Chem. 1986;32:1616-1617.
13. Banner W Jr, Bach P, Burk B, Freestone S, Gooch WM 3rd. Influence of assay methods on serum concentrations of digoxin during FAB fragment treatment. J Toxicol Clin Toxicol. 1992;30:259-267.
14. Stone JA, Soldin SJ. An update on digoxin. Clin Chem. 1989;35:1326-1331.
15. Smolarz A, Roesch E, Lenz E, Neubert H, Abshagen P. Digoxin specific antibody (Fab) fragments in 34 cases of severe digitalis intoxication. J Toxicol Clin Toxicol. 1985;23:327-340.
16. Kramer WG, Kolibash AJ, Bathala MS, Visconti JA, Lewis RP, Reuning RH. Digoxin bioavailability: evaluation of a generic tablet and proposed FDA guidelines. J Pharm Sci. 1977;66:1720-1722.
17. Smith TW, Haber E, Yeatman L, Butler VP, Jr. Reversal of advanced digoxin intoxication with Fab fragments of digoxinspecific antibodies. N Engl J Med. 1976;294:797-800.